Dr. Luke on Ongoing Studies With Immunotherapy in Melanoma

Jason J. Luke, MD
Published: Wednesday, Dec 28, 2016



Jason J. Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses ongoing studies exploring immunotherapy for the treatment of patients with melanoma.

Despite the various FDA approvals of immunotherapy agents in the field, Luke says experts still do not understand them that well, in terms of what sequence to use them in and at what dose to administer them. There are emerging phase II data looking at sequencing immunotherapies, as well as data exploring a higher dose of ipilimumab (Yervoy) in these patients.

Additionally, clinical trials are exploring combinations of the targeted agents cobimetinib (Cotellic), dabrafenib (Tafinlar), trametinib (Mekinist), and vemurafenib (Zelboraf), with PD-1/PD-L1 antibodies in phase III trials. These appear to be exciting, he adds. Moreover, researchers are continuing to study the biology of immunotherapy and determining optimal combination partners that may even be more effective for patients. These could potentially include IDO inhibitors.

Furthermore, combinations with the PD-1/PD-L1 inhibitors plus talimogene laherparepvec (T-VEC; Imlygic) are also being studied in clinical trials, Luke says.


Jason J. Luke, MD, an assistant professor of Medicine at the University of Chicago Medicine, discusses ongoing studies exploring immunotherapy for the treatment of patients with melanoma.

Despite the various FDA approvals of immunotherapy agents in the field, Luke says experts still do not understand them that well, in terms of what sequence to use them in and at what dose to administer them. There are emerging phase II data looking at sequencing immunotherapies, as well as data exploring a higher dose of ipilimumab (Yervoy) in these patients.

Additionally, clinical trials are exploring combinations of the targeted agents cobimetinib (Cotellic), dabrafenib (Tafinlar), trametinib (Mekinist), and vemurafenib (Zelboraf), with PD-1/PD-L1 antibodies in phase III trials. These appear to be exciting, he adds. Moreover, researchers are continuing to study the biology of immunotherapy and determining optimal combination partners that may even be more effective for patients. These could potentially include IDO inhibitors.

Furthermore, combinations with the PD-1/PD-L1 inhibitors plus talimogene laherparepvec (T-VEC; Imlygic) are also being studied in clinical trials, Luke says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Evolving Roles for Targeted Melanoma Therapies: Assessing Rapid Progress in the Field and Looking Toward Future CombinationsFeb 28, 20191.5
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Publication Bottom Border
Border Publication
x